NasdaqGS:QUREBiotechs
Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures
Why the new lawsuit matters for uniQure stock
A fresh securities fraud class action against uniQure (NasdaqGS:QURE) is putting a spotlight on how the company previously described AMT-130’s pivotal Huntington’s disease data and its interactions with the FDA.
The complaint challenges earlier messaging around biomarker results, comparisons with the ENROLL HD dataset, and the timeline for a potential Biologics License Application, which together influence how investors assess uniQure’s regulatory...